» Articles » PMID: 15905560

Kinetoplastid Membrane Protein-11 DNA Vaccination Induces Complete Protection Against Both Pentavalent Antimonial-sensitive and -resistant Strains of Leishmania Donovani That Correlates with Inducible Nitric Oxide Synthase Activity and IL-4...

Overview
Journal J Immunol
Date 2005 May 21
PMID 15905560
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

The emergence of an increasing number of Leishmania donovani strains resistant to pentavalent antimonials (SbV), the first line of treatment for visceral leishmaniasis worldwide, accounts for decreasing efficacy of chemotherapeutic interventions. A kinetoplastid membrane protein-11 (KMP-11)-encoding construct protected extremely susceptible golden hamsters from both pentavalent antimony responsive (AG83) and antimony resistant (GE1F8R) virulent L. donovani challenge. All the KMP-11 DNA vaccinated hamsters continued to survive beyond 8 mo postinfection, with the majority showing sterile protection. Vaccinated hamsters showed reversal of T cell anergy with functional IL-2 generation along with vigorous specific anti-KMP-11 CTL-like response. Cytokines known to influence Th1- and Th2-like immune responses hinted toward a complex immune modulation in the presence of a mixed Th1/Th2 response in conferring protection against visceral leishmaniasis. KMP-11 DNA vaccinated hamsters were protected by a surge in IFN-gamma, TNF-alpha, and IL-12 levels along with extreme down-regulation of IL-10. Surprisingly the prototype candidature of IL-4, known as a disease exacerbating cytokine, was found to have a positive correlation to protection. Contrary to some previous reports, inducible NO synthase was actively synthesized by macrophages of the protected hamsters with concomitant high levels of NO production. This is the first report of a vaccine conferring protection to both antimony responsive and resistant Leishmania strains reflecting several aspects of clinical visceral leishmaniasis.

Citing Articles

An update on recombinant vaccines against leishmaniasis.

Shital S, Madan E, Selvapandiyan A, Ganguly N Indian J Med Res. 2024; 160(3&4):323-337.

PMID: 39632642 PMC: 11619067. DOI: 10.25259/IJMR_1040_2024.


New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine.

Oliveira D, Zaldivar M, Goncalves A, Resende L, Mariano R, Pereira D Vaccines (Basel). 2024; 12(3).

PMID: 38543905 PMC: 10975552. DOI: 10.3390/vaccines12030271.


Recognition of Immunoreactive Proteins in Leishmania infantum Amastigote-Like and Promastigote Using Sera of Visceral Leishmaniasis Patients: a Preliminary Study.

Heidari S, Hajjaran H, Mohebali M, Akhoundi B, Gharechahi J Acta Parasitol. 2024; 69(1):533-540.

PMID: 38227109 DOI: 10.1007/s11686-023-00764-0.


The use of recombinant K39, KMP11, and crude antigen-based indirect ELISA as a serological diagnostic tool and a measure of exposure for cutaneous leishmaniasis in Sri Lanka.

Karunathilake C, Alles N, Dewasurendra R, Weerasinghe I, Chandrasiri N, Piyasiri S Parasitol Res. 2023; 123(1):77.

PMID: 38157062 PMC: 11263736. DOI: 10.1007/s00436-023-08103-y.


LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis.

Lacey C, Musa A, Khalil E, Younis B, Osman M, Wiggins R Wellcome Open Res. 2023; 7:200.

PMID: 37252616 PMC: 10213822. DOI: 10.12688/wellcomeopenres.17951.1.